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Abstract
Background: Spinal cord electrical stimulation (SCS) has shown to be a treatment option for patients suffering from angina
pectoris CCS III-IV although being on optimal medication and not suitable for conventional treatment strategies, e.g. CABG or
PTCA. Although many studies demonstrated a clear symptomatic relief under SCS therapy, there are only a few short-term
studies that investigated alterations in cardiac ischemia. Therefore doubts remain whether SCS has a direct effect on myocardial
perfusion.
Methods: A prospective study to investigate the short- and long-term effect of spinal cord stimulation (SCS) on myocardial
ischemia in patients with refractory angina pectoris and coronary multivessel disease was designed. Myocardial ischemia was
measured by MIBI-SPECT scintigraphy 3 months and 12 months after the beginning of neurostimulation. To further examine the
relation between cardiac perfusion and functional status of the patients we measured exercise capacity (bicycle ergometry and
6-minute walk test), symptoms and quality of life (Seattle Angina Questionnaire [SAQ]), as well.
Results: 31 patients (65 ± 11 SEM years; 25 male, 6 female) were included into the study. The average consumption of short
acting nitrates (SAN) decreased rapidly from 12 ± 1.6 times to 3 ± 1 times per week. The walking distance and the maximum
workload increased from 143 ± 22 to 225 ± 24 meters and 68 ± 7 to 96 ± 12 watt after 3 months. Quality of life increased
(SAQ) significantly after 3 month compared to baseline, as well. No further improvement was observed after one year of
treament. Despite the symptomatic relief and the improvement in maximal workload computer based analysis (Emory Cardiac
Toolbox) of the MIBI-SPECT studies after 3 months of treatment did not show significant alterations of myocardial ischemia
compared to baseline (16 patients idem, 7 with increase and 6 with decrease of ischemia, 2 patients dropped out during initial
test phase). Interestingly, in the long-term follow up after one year 16 patients (of 27 who completed the one year follow up)
showed a clear decrease of myocardial ischemia and only one patient still had an increase of ischemia compared to baseline.
Conclusion: Thus, spinal cord stimulation not only relieves symptoms, but reduces myocardial ischemia as well. However, since
improvement in symptoms and exercise capacity starts much earlier, decreased myocardial ischemia might not be a direct effect
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of neurostimulation but rather be due to a better coronary collateralisation because of an enhanced physical activity of the
patients.
Introduction
In spite of continuous improvements in revascularization
techniques, there remain patients ineligible for coronary
artery bypass graft surgery (CABG) and coronary angi-
oplasty. Those patients frequently suffer from severe
angina, CCS (Canadian Cardiovascular Society) class III
to IV; their complaints may not be managed even with
optimized drug treatment. An estimated 0.5–1% of cathe-
terized patients belongs to this category. Taking into
account the above numbers of catheterizations, in Ger-
many alone there are up to 6000 patients per year suffer-
ing from angina-related pain without an option for
revascularization.
Those patients master their daily lives only by an excessive
use of short-acting nitrates and avoiding physical activity.
Regular use of morphine is not uncommon. A vicious cir-
cle is established: The pain limits physical activity thus
inducing further decrease of physical fitness. Frequent
hospitalizations, visits to the attending physician and the
need for intensive care (when a myocardial infarction is
suspected) cause immense costs for the health care
system.
Based on the "gate control theory" [1] Wall and Sweet [2]
were the first to use electric stimulation of spinal nerves or
dorsal roots in treating chronic pain. This new technique
called spinal cord stimulation (SCS) caused a significant
decrease in ischemia-related pain and an increased per-
fusion of capillaries in skeletal muscle and skin through
stimulating different types of neurons and fibers in the
spinal cord.
In recent years the number of studies showing decreasing
symptoms, improved quality of life and less signs of myo-
cardial ischemia (mostly measured by ECG) in SCS-
treated patients rose continuously [3-13]. However, the
exact mode of action and the influence on myocardial per-
fusion are yet unknown. Very recently Jessurun and co-
workers could demonstrate an improved myocardial per-
fusion in TENS (transcutaneous electric neurostimula-
tion) treated patients with syndrome X after 4 weeks [14].
Besides a study with 9 patients and a 6 week follow up
[15], there exist no long-term data about myocardial
ischemia under SCS in patients with coronary artery dis-
ease. In our trial, we therefore investigated not only the
development of symptoms, quality of life and exercise
capacity but also the myocardial perfusion measured by
MIBI-SPECT (single photon emission computer tomogra-
phy) in a one year follow up of 31 patients with CAD and
intractable angina.
Materials and methods
Patients
Between March 1999 and May 2003 31 patients were
included in the study. Criteria for accepting a patient was
a refractory angina CCS III-IV in spite of optimized medi-
cal therapy (ACE inhibitors, aspirin, β -blockers, statins,
calcium channel blockers, nitrates). All patients had a cor-
onary angiogram in the last 3 months before screening
and were discussed in detail for possibility of CABG and/
or PCI (percutaneus coronary intervention) by a special-
ized team of cardiologists and heart surgeons. Only if
none of these revascularization techniques was consid-
ered as suitable was the patient included in the trial. Since
relieving of pain is the main aim of SCS treatment we only
included patients with angina CCS III-IV without relevant
symptoms of heart failure. Hence, patients with a left ven-
tricular ejection fraction less than 40% or a NYHA class
greater than II were excluded from the study. All inclusion
and exclusion criteria are listed in table 1.
Implantation of the electrode
The electrode was placed in the epidural space at the level
of Th4-5 through a small skin incision under local
anesthesia, and then it was moved up to C7-Th1 subcuta-
neously. Correct placement was defined by test-stimula-
tion and interviewing the patient. Patients should
experience paraesthesia in the same dermatome normally
affected by angina. After final placement, the electrode
was connected to an external stimulator, which allowed
the patient to test the effects of SCS for 3–4 days. After-
wards the final stimulator (Medtronic Itrel III) was
implanted subcutaneous in the lateral abdomen and con-
nected to the electrode. The stimulator was controlled
through an external device by the patient allowing to
change the amplitude of the stimulus or to switch it on/
off.
During the course of the study, examinations were sched-
uled after four weeks, three months (with MIBI-SPECT
and SAQ), twelve month (with MIBI-SPECT and SAQ)
and whenever wished by the patients.
Exercise capacity
The bicycle ergometry protocol began at a workload of 25
Watt and increases in 25 Watt increments every 2 minutes.
Exercise was terminated by the patient, when angina pec-
toris occurred or he was exhausted. Criteria for earlyCurrent Controlled Trials in Cardiovascular Medicine 2005, 6:7 http://cvm.controlled-trials.com/content/6/1/7
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termination of exercise were ischemic ST-segment depres-
sion > 2 mm; ventricular or supraventricular tachycardia;
and a decrease or abnormal elevation in systolic blood
pressure. In our study in none of the patients termination
was necessary because of tachycardia or abnormal blood
pressure.
The six-minute walk test was performed using an internal
hallway with a marked distance of 50 meters. Patients
were instructed to walk the distance at their own pace but
to cover as much ground as possible. They were allowed
to stop and rest during the test if needed.
Nitrate intake and Seattle Angina Questionnaire (SAQ)
The SAQ is a self-administered, disease-specific measure
for patients with CAD that has previously been demon-
strated to be valid, reproducible, and sensitive to clinical
change [16-18]. The SAQ measures five dimensions of
coronary artery disease: patients' physical limitations
caused by angina, the frequency of and recent changes in
their symptoms (angina frequency and angina stability),
their satisfaction with treatment and the degree to which
they perceive their disease to affect their quality of life.
Each scale is transformed to a score of 0 to 100, where
higher scores indicate better function (e.g. less physical
limitation, less angina, and better quality of life).
The amount of short acting nitrates (SAN) during one
week was reported by the patients at every visit in the
clinic. For our analysis we used average SAN consumption
after 3 and 12 months.
Myocardial scintigraphy (MIBI-SPECT)
SPECT- examinations were run on two days, one day
under resting conditions, the second day after stress, using
740 MBq 99-Technetium-MIBI. Stress was induced either
by physical exercise (bicycle ergometry) or by dobutamine
injection (10, 20, 30, 40 µg per /kg/ min). Scanning was
run one hour after the injection in the stress examinations
and two hours after resting-conditions. To compare con-
ditions before SCS implantation and during follow up
stress scans were made at a comparable rate pressure
product.
The camera was a three-head gamma camera with a LEHR-
(low-energy-high-resolution) -collimator (prism 3000,
Picker/Philips; matrix 128 × 128, 40 steps with 3° each,
20 seconds per step). For generating tomograms in short
and long axis views, a filtered backprojection technique
with additional semiquantitative polarmap analysis was
used. SPECT examinations took place prior to the implan-
tation of the SCS system as well as three and twelve
months after.
Myocardial scintigraphy is usually used to access regional
perfusion, e.g. after a heart attack or PCI. However, if the
total myocardial perfusion in one patient is to be exam-
ined over a course of time, one frequently encounters the
reduction of ischemia in one area combined with
increased ischemia in another, e.g. improved perfusion in
the anterior myocardium with reduced perfusion in the
posterior myocardium. This makes it difficult to judge
whether conditions have improved or actually worsened.
To meet this problem, results were interpreted with the
„Emory Cardiac Toolbox“ (Emory Medical Device
Group). This software compares the perfusion found in
the patient to a virtual normal perfusion, setting the nor-
mal nuclide distribution- that is the normal perfusion- as
1. If a patient has a score of 0.5 (50% of normal radionu-
clide distribution and myocardial perfusion) in the initial
scan and reaches a score of 0.8 (80% of normal radionu-
clide distribution and myocardial perfusion) in follow-up
examinations this means total perfusion has improved,
even if perfusion of some areas has decreased. The score is
not determined in direct comparison of two SPECT-scans,
but by comparing each scan to virtual normal results. This
software makes it possible to monitor the development of
myocardial perfusion over a course of time.
In spite of this method, accessing the total perfusion
remains more complex than judging regional perfusion
(e.g. after PCI or heart attack). We therefore decided to
limit our interpretation of data on the development of
myocardial perfusion in the course of the study as follows:
A score improved at least 0.2 was judged an improvement;
a score lowered by 0.2 was regarded as a worsened state. A
score of ± = 0.1 was defined as unchanged. We left out any
semi-quantitative scores with standard deviation as we felt
they would over-interpret the data.
Table 1: Inclusion and exclusion criteria
Inclusion criteria
Chronic coronary artery disease (CAD)
Evidence of ischemia in MIBI-SPECT examination
Coronary angiogram in the last 3 months
Angina pectoris, CCS III-IV
Optimal medical treatment (Beta-blocker, ACE-inhibitor or AT1-
antagonist, Ca2+-antagonist, ASS, CSE-inhibitor, long-acting nitrate 
[LAN])
Not suitable for percutaneous coronary intervention (PCI) or 
aortocoronary bypass surgery (CABG) after discussion with a 
team of specialists (cardiologists and heart surgeons)
Exclusion criteria
Myocardial infarction or unstable in the last 3 months
Pacemaker with unipolar electrode
Relevant valvular heart disease
Symptomatic heart failure > NYHA II
Left ventricular ejection fraction (LVEF) < 40%Current Controlled Trials in Cardiovascular Medicine 2005, 6:7 http://cvm.controlled-trials.com/content/6/1/7
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Statistical analysis
Data are presented as mean ± 95 % confidence interval.
Differences among groups were compared by an unpaired
t-test. Significance was assigned to a value of p < 0.05.
Results
Patients
The mean age was 65 years (± 11). As angina is more com-
mon in men, there were more men (n = 26) than women
(n = 5) enrolled. 26 Patients suffered from a 3-vessel cor-
onary artery disease, 5 from a 2-vessel disease. All patients
had undergone bypass surgery (n = 24) and/or PCI (stent)
(n = 28); five patients already underwent transmyocardial
laser revascularization. Detailed patient characteristics are
presented in table 2. Drug therapy had been optimized;
apart from morphine intake it was not changed signifi-
cantly during the trial's course (see table 3).
2 patients did not feel a positive effect of SCS on their
symptoms in the test period (after implantation of the
electrodes and using the external stimulator) and there-
fore dropped out during the initial phase of the study. SCS
device was explanted in another patient after 8 months
because of a lack of anti-anginal effect, too. Unfortu-
nately, after explantation of the SCS device none of the 3
patients joined further follow up visits or MIBI-SPECT
examinations. One patient died because of a liver cell
cancer one month before one year visit. Cancer was not
known at time of inclusion in the study.
Exercise capacity
The physical fitness of patients improved as measured by
six-minute walk test and bicycle ergometry already after 3
months (142.74 ± 22.13 vs. 224.83 (± 23.96) meters and
67.50 ± 7.11 vs. 96.43 ± 11.74 watt) and maintained at
this level after one year (250.56 ± 25.24 meters; 98.08 ±
8.12 watt, see table 4). The 3 months follow up was fin-
ished by 29, the one year follow up by 27 patients (see
above).
Symptoms, nitrate intake and Seattle Angina 
Questionnaire (SAQ)
Apart from the three patients who decided to have the
electrodes explanted as they felt no relieve in symptoms,
all other patients felt a significant decrease of symptoms
due to treatment with SCS (28 out of 31).
Eleven out of twelve patients treated with morphine at
baseline no longer needed morphine at all; one patient
was at least able to reduce the dose from 60 mg morphine
sulphate (MST®) to 20 mg per day. Two patients no longer
needed long-acting nitrates (see table 3). The use of short-
acting nitrates (SAN) was lowered significantly, as well
(12.35 ± 1.6 vs. 3.38 ± 0.96 and 2.78 ± 0.90 times per
week, see table 4).
The Seattle Angina Questionnaire showed a significant
increase in quality of Life after 3 months under SCS treat-
ment (SAQ score 39 at baseline vs. 73). After one year the
improved quality of life maintained (score 75). Scores for
physical limitation 33 vs. 47 [3 months] and 48 [1 year]),
angina stability (30 vs. 51 and 53) and frequency (26 vs.
53 and 54) improved significantly, as well (see figure 1).
Myocardial perfusion (MIBI-SPECT)
As described above, data were interpreted with the
„Emory Cardiac Toolbox“ software. The examinations 3
months after SCS implantation (n = 29) showed
unchanged SPECT results in most patients (n = 16). Only
Table 2: Patient characteristics at baseline
Gender: male/female 26 / 5
Mean Age (range), years 65 (35–79)
Diagnosis
3-vessel coronary artery disease 26 (84%)
2-vessel coronary artery disease 5 (16%)
History, number of patients and percentage
Myocardial infarction 23 (74%)
Heart Failure >NYHA II 0 (0%)
Previous coronary intervention (PTCA/Stent) 28 (90%)
Previous CABG 24 (77%)
TMLR 5 (16%)
Cerebrovascular Disease (stroke and TIA) 5 (16%)
Symptomatic peripheral vascular disease 4 13%)
Hypertension 16 (52%)
Diabetes mellitus 7 (23%)
Hyperlipoproteinemia 23 (74%)
Adipositas (BMI >30) 8 (26%)
Nicotine abuse past/current 24 / 6 (77% / 19%)
NYHA = New York Heart Association, PTCA = percutaneous 
transluminal coronary angioplasty, CABG = coronary artery bypass 
graft, TMLR = transmyocardial laser revascularization, TIA = 
transitoric ischemic attack, BMI = body mass index
Table 3: Medication of the patients at baseline and one year 
follow up
Baseline 
(n = 31)
1 Year 
(n = 27)
Beta-blocker 31 (100%) 27 (100%)
ACE-Inhibior/AT1-Antagonist 29 (94%) 26 (96%)
Ca++-Antagonist 26 (84%) 24 (89%)
CSE-inhibitor 31 (100%) 27 (100%)
Long-acting nitrate 31 (100%) 25 (93%)
Morphine derivate 12 (39%) 1 (4%)
Medication of the patients at baseline (n = 31) and one year follow up 
(n = 27). Before one year follow up SCS device was explanted in 3 
patients (2 during test phase, one after 8 months). One patient died 
before last visit.Current Controlled Trials in Cardiovascular Medicine 2005, 6:7 http://cvm.controlled-trials.com/content/6/1/7
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6 patients showed a better myocardial perfusion while in
7 ischemia worsened (figure 2). Interestingly, a shift
towards an improved myocardial perfusion could be
found after one year. Of 27 examined patients a worsened
situation compared to baseline was found only in one
patient. 16 patients showed clearly less myocardial
ischemia. Results of the MIBI-SPECT analysis with the
"Emory Cardiac Toolbox" software are shown in figure 2.
Black arrows indicate the shift of the patients between the
three groups (worse, equal or improved myocardial per-
fusion) during 3 and 12 months follow up. An exemplary
scintigram prior to and twelve months after implantation
is shown in figure 3.
Complications
No serious complications were caused by the implanta-
tion of the neurostimulators. Neither injuries of the spinal
cord nor infections occurred. The major problem in the
beginning were a dislocation of the electrodes (n = 4).
This could be remedied without any difficulties by surgi-
cal re-intervention. As the operating surgeons became
more experienced, electrode dislocations requiring surgi-
cal intervention did not happen any longer. Small disloca-
tions could be handled easily by re-programming the
stimulation parameters.
Discussion
This is the first clinical report with a long term follow up
of myocardial perfusion measured by MIBI-SPECT in
patients with multivessel coronary artery disease under
spinal cord stimulation (SCS). Like in prior investigations
we additionally measured symptoms, quality of life and
exercise capacity of the patients, as well.
There was an early reduction of angina related symptoms
under SCS treatment. Patients showed not only a signifi-
cant reduction of SAN consumption (table 4) but also less
use of morphine derivates already in the first weeks under
neurostimulation therapy (table 3). The analysis of the
self-administered Seattle Angina questionnaire (SAQ)
resulted in improved scores for physical limitation,
angina frequency, angina stability and quality of life after
3 months with unchanged results after one year (figure 1).
Table 4: SAN consumption per week and results of bicycle ergometry and 6-minute walk test at baseline and follow up
Baseline 3 Months 1 Year
SAN Consumption amount/week 12.35 (± 1.6) 3.38 (± 0.96)* 2.78 (± 0.90)*
Bicycle Ergometry watt 67.50 (± 7.11) 96.43 (± 11.74)* 98.08 (± 8.12)*
6-Minute Walk meters 142.74 (± 22.13) 224.83 (± 23.96)* 250.56 (± 25.24)*
* = p < 0.05 compared to baseline. Results are listed in mean ± 95% confidence interval.
Results from the Seattle Angina Questionnaire (SAQ) Figure 1
Results from the Seattle Angina Questionnaire (SAQ). * = p 
< 0.05 compared to baseline. Results are in mean ± 95% con-
fidence interval (error indicator).
Results of the MIBI-SPECT analysis with the "Emory Cardiac  Toolbox" software Figure 2
Results of the MIBI-SPECT analysis with the "Emory Cardiac 
Toolbox" software. Black arrows indicate the shift of the 
patients between the three groups (worse, equal or 
improved myocardial perfusion) during 3 and 12 months fol-
low up.
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In opposite to the early functional improvement of the
patients (symptoms, physical activity, quality of life),
myocardial ischemia measured by MIBI-SPECT was not
decreased after 3 months. 22 patients showed unchanged
or even more ischemia compared to baseline before SCS
implantation (figure 2). After one year – while functional
parameters (exercise capacity, quality of life etc.) did not
show a further change – myocardial perfusion was
remarkable improved in many patients (16 of 27). Only
one patient still had more cardiac ischemia than in base-
line examination (figure 2). Interestingly, the score for
physical limitation (SAQ) of this patient did not improve
very much, as well (55 [baseline), 62 [3 months], 58 [1
year]).
Since a direct effect of SCS on myocardial perfusion
should be established early after beginning of the neuros-
timulation, one would have expected to see alterations in
the MIBI-SPECT after 3 months. The improved myocar-
dial perfusion found after one year might therefore be due
to the development of collateral vessels associated with
increased physical fitness.
Two recent studies reported alterations in myocardial
blood flow already after 4 or 6 weeks [22,23]. Both found
a homogenization of myocardial perfusion measured by
positron emission tomography (PET) in patients with
multivessel disease or syndrome X. They suggested that
the change in myocardial blood flow can be denoted as a
steal phenomenon at the microcirculatory level eventually
mediated by a direct effect of SCS on coronary vasomo-
tion. However, they could not find an improved resting
myocardial blood flow in their studies, as well. Hautvast
and co-workers even found a decreased flow reserve under
dipyridamole stress [22]. Thus, our study is the first to
show that myocardial perfusion can improve under neu-
rostimulation in patients with coronary multivessel dis-
ease. Since we applied a different method to measure
myocardial ischemia, we cannot provide data regarding a
possible homogenization of cardiac blood flow in the
early phase of spinal cord stimulation. But our data sug-
gest that the main effect of SCS treatment is anti-sympto-
matic and changes in myocardial ischemia are rather
secondary and might be due to increased physical activity.
This hypothesis is supported by data of Belardinelli and
co-workers, who demonstrated that moderate exercise
training improved myocardial perfusion measured by
thallium scintigraphy in patients with chronic coronary
artery disease [19]. If this decrease of myocardial ischemia
does also improve the prognosis of the patients cannot be
answered yet.
Scintigram of one patient prior to (left) and twelve months after (right) implantation Figure 3
Scintigram of one patient prior to (left) and twelve months after (right) implantation. Each first line shows a stress scan, the 
second line the appendant rest scan. The third line shows again a stress scan etc. After one year clearly reduced hibernation 
resp. prolonged ischemia of the anterior LV wall (arrows vertical long axis views). Less pronounced reduction of the ischemia 
of the lateral LV wall (arrow heads short axis views).
Baseline 12 months follow upCurrent Controlled Trials in Cardiovascular Medicine 2005, 6:7 http://cvm.controlled-trials.com/content/6/1/7
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Nevertheless, the impressive improvement of angina-
related symptoms, the exercise ability and last but not
least the increase in quality of life of 90% (28/31) of our
patients in a one year follow up supports the data of other
studies which treated patients with CAD and refractory
angina with spinal cord stimulation.
In a recent study, which included 32 patients with a fol-
low up of 65 months, SCS relieved angina effectively also
after long-term treatment without development of toler-
ance. SAQ scores still were improved after years [20].
Maintenance of increased exercise ability for years might
be an ongoing stimulus for coronary collateralization.
In conclusion electrical spinal cord stimulation is a valua-
ble therapeutic option for the treatment of refractory
angina pectoris in patients not suitable for coronary revas-
cularization procedures. Additionally, the symptomtic
relief may allow more physical activity which might
induce coronary collateralization resulting in an
improved myocardial perfusion.
Study limitations
Since it is difficult to conduct placebo-controlled trials
with electrical neuromodulation, because there is no alter-
native for the paraesthesia induced by the neurostimula-
tors, our study has -like others- no placebo group.
However, measurement of myocardial perfusion with
MIBI-SPECT is an objective parameter not impressionable
by the patient [21,22]. As placebo effect is generally
believed to decrease with time [23-26] the sustained relief
of symptoms over one year in this study seem to contra-
dict the estimation that placebo effects are the major
mode of action of SCS treatment. To finally prove whether
the altered myocardial perfusion is due to direct SCS
effects or increased exercise ability with improved collat-
eralization a control group without SCS but with exercise
training would be necessary.
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